289000EGP
- Active ingredient
- polatuzumab
- Strength
- 140mg
- Form
- vial
- Manufacturer
- roche
- Route
- injection
Uses
Antineoplastic agent used in combination regimens for certain adults with diffuse large B-cell lymphoma and other eligible B-cell lymphomas.
Do not use if
No specific contraindications are listed in the product labeling.
Side effects
Peripheral neuropathy, infusion-related reactions, myelosuppression, infections, fatigue, and gastrointestinal adverse effects may occur.
Warnings
Monitor for neuropathy, infusion reactions, bone marrow suppression, and serious infections during treatment.
How it works
CD79b-directed antibody-drug conjugate that delivers a microtubule inhibitor to dividing B cells, resulting in cell death.
Storage
Store refrigerated at 2–8°C in the original carton protected from light. Do not freeze or shake.
